These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

707 related items for PubMed ID: 16227402

  • 1. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade.
    Shi Y, Yan H, Frost P, Gera J, Lichtenstein A.
    Mol Cancer Ther; 2005 Oct; 4(10):1533-40. PubMed ID: 16227402
    [Abstract] [Full Text] [Related]

  • 2. Rapamycin promotes vascular smooth muscle cell differentiation through insulin receptor substrate-1/phosphatidylinositol 3-kinase/Akt2 feedback signaling.
    Martin KA, Merenick BL, Ding M, Fetalvero KM, Rzucidlo EM, Kozul CD, Brown DJ, Chiu HY, Shyu M, Drapeau BL, Wagner RJ, Powell RJ.
    J Biol Chem; 2007 Dec 07; 282(49):36112-20. PubMed ID: 17908691
    [Abstract] [Full Text] [Related]

  • 3. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt.
    O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, Baselga J, Rosen N.
    Cancer Res; 2006 Feb 01; 66(3):1500-8. PubMed ID: 16452206
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation.
    Wang X, Yue P, Chan CB, Ye K, Ueda T, Watanabe-Fukunaga R, Fukunaga R, Fu H, Khuri FR, Sun SY.
    Mol Cell Biol; 2007 Nov 01; 27(21):7405-13. PubMed ID: 17724079
    [Abstract] [Full Text] [Related]

  • 5. Insulin-like growth factor I-mediated protection from rapamycin-induced apoptosis is independent of Ras-Erk1-Erk2 and phosphatidylinositol 3'-kinase-Akt signaling pathways.
    Thimmaiah KN, Easton J, Huang S, Veverka KA, Germain GS, Harwood FC, Houghton PJ.
    Cancer Res; 2003 Jan 15; 63(2):364-74. PubMed ID: 12543789
    [Abstract] [Full Text] [Related]

  • 6. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779.
    Shi Y, Gera J, Hu L, Hsu JH, Bookstein R, Li W, Lichtenstein A.
    Cancer Res; 2002 Sep 01; 62(17):5027-34. PubMed ID: 12208757
    [Abstract] [Full Text] [Related]

  • 7. Regulation of insulin/insulin-like growth factor-1 signaling by proteasome-mediated degradation of insulin receptor substrate-2.
    Rui L, Fisher TL, Thomas J, White MF.
    J Biol Chem; 2001 Oct 26; 276(43):40362-7. PubMed ID: 11546773
    [Abstract] [Full Text] [Related]

  • 8. Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis.
    Yan H, Frost P, Shi Y, Hoang B, Sharma S, Fisher M, Gera J, Lichtenstein A.
    Cancer Res; 2006 Feb 15; 66(4):2305-13. PubMed ID: 16489035
    [Abstract] [Full Text] [Related]

  • 9. Mammalian target of rapamycin pathway regulates insulin signaling via subcellular redistribution of insulin receptor substrate 1 and integrates nutritional signals and metabolic signals of insulin.
    Takano A, Usui I, Haruta T, Kawahara J, Uno T, Iwata M, Kobayashi M.
    Mol Cell Biol; 2001 Aug 15; 21(15):5050-62. PubMed ID: 11438661
    [Abstract] [Full Text] [Related]

  • 10. A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1.
    Ozes ON, Akca H, Mayo LD, Gustin JA, Maehama T, Dixon JE, Donner DB.
    Proc Natl Acad Sci U S A; 2001 Apr 10; 98(8):4640-5. PubMed ID: 11287630
    [Abstract] [Full Text] [Related]

  • 11. Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma.
    Cirstea D, Hideshima T, Rodig S, Santo L, Pozzi S, Vallet S, Ikeda H, Perrone G, Gorgun G, Patel K, Desai N, Sportelli P, Kapoor S, Vali S, Mukherjee S, Munshi NC, Anderson KC, Raje N.
    Mol Cancer Ther; 2010 Apr 10; 9(4):963-75. PubMed ID: 20371718
    [Abstract] [Full Text] [Related]

  • 12. Signal pathways involved in activation of p70S6K and phosphorylation of 4E-BP1 following exposure of multiple myeloma tumor cells to interleukin-6.
    Shi Y, Hsu JH, Hu L, Gera J, Lichtenstein A.
    J Biol Chem; 2002 May 03; 277(18):15712-20. PubMed ID: 11872747
    [Abstract] [Full Text] [Related]

  • 13. Muscarinic-receptor-mediated inhibition of insulin-like growth factor-1 receptor-stimulated phosphoinositide 3-kinase signalling in 1321N1 astrocytoma cells.
    Batty IH, Fleming IN, Downes CP.
    Biochem J; 2004 May 01; 379(Pt 3):641-51. PubMed ID: 14769130
    [Abstract] [Full Text] [Related]

  • 14. Nutrients suppress phosphatidylinositol 3-kinase/Akt signaling via raptor-dependent mTOR-mediated insulin receptor substrate 1 phosphorylation.
    Tzatsos A, Kandror KV.
    Mol Cell Biol; 2006 Jan 01; 26(1):63-76. PubMed ID: 16354680
    [Abstract] [Full Text] [Related]

  • 15. Activation of the mammalian target of rapamycin pathway acutely inhibits insulin signaling to Akt and glucose transport in 3T3-L1 and human adipocytes.
    Tremblay F, Gagnon A, Veilleux A, Sorisky A, Marette A.
    Endocrinology; 2005 Mar 01; 146(3):1328-37. PubMed ID: 15576463
    [Abstract] [Full Text] [Related]

  • 16. Insulin-like growth factor-I inhibits transcriptional responses of transforming growth factor-beta by phosphatidylinositol 3-kinase/Akt-dependent suppression of the activation of Smad3 but not Smad2.
    Song K, Cornelius SC, Reiss M, Danielpour D.
    J Biol Chem; 2003 Oct 03; 278(40):38342-51. PubMed ID: 12876289
    [Abstract] [Full Text] [Related]

  • 17. Insulin-like growth factor I induces preferential degradation of insulin receptor substrate-2 through the phosphatidylinositol 3-kinase pathway in human neuroblastoma cells.
    Kim B, van Golen CM, Feldman EL.
    Endocrinology; 2005 Dec 03; 146(12):5350-7. PubMed ID: 16150916
    [Abstract] [Full Text] [Related]

  • 18. Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma.
    Kuhn DJ, Berkova Z, Jones RJ, Woessner R, Bjorklund CC, Ma W, Davis RE, Lin P, Wang H, Madden TL, Wei C, Baladandayuthapani V, Wang M, Thomas SK, Shah JJ, Weber DM, Orlowski RZ.
    Blood; 2012 Oct 18; 120(16):3260-70. PubMed ID: 22932796
    [Abstract] [Full Text] [Related]

  • 19. Defining the role of TORC1/2 in multiple myeloma.
    Maiso P, Liu Y, Morgan B, Azab AK, Ren P, Martin MB, Zhang Y, Liu Y, Sacco A, Ngo H, Azab F, Quang P, Rodig SJ, Lin CP, Roccaro AM, Rommel C, Ghobrial IM.
    Blood; 2011 Dec 22; 118(26):6860-70. PubMed ID: 22045983
    [Abstract] [Full Text] [Related]

  • 20. The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma.
    Baumann P, Mandl-Weber S, Oduncu F, Schmidmaier R.
    Exp Cell Res; 2009 Feb 01; 315(3):485-97. PubMed ID: 19071109
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.